Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Xiangying Xia"'
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Aberrant activation of RAS-RAF-MEK-ERK signaling pathway has been implicated in more than one-third of all malignancies. MEK inhibitors are promising therapeutic approaches to target this signaling pathway. Though four MEK inhibitors have
Externí odkaz:
https://doaj.org/article/b974c78211d44fed8927e24c4cefca76
Autor:
Dan Zhang, Xiangying Xia, Xixi Wang, Peng Zhang, Weiliang Lu, Yamei Yu, Shi Deng, Hanshuo Yang, Hongxia Zhu, Ningzhi Xu, Shufang Liang
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170453 (2017)
Progesterone receptor membrane component 1 (PGRMC1) is widely observed with an elevated level in multiple human cancers. However, the roles of PGRMC1 in renal cancer are not clear and merit further study. In this report, we made a systematic, integra
Externí odkaz:
https://doaj.org/article/2f0ff2c8adeb4f3caba903eda294ba1a
Publikováno v:
International journal of cancer. 145(2)
Mutations in RAS/RAF occur in large portion of malignancies and are associated with aggressive clinical behaviors and poor prognosis. Therefore, we developed a novel benzoxazole compound (KZ-001) as a highly potent and selective MEK 1/2 inhibitor. Ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54646c217b1b3a3bcc971b6062c64021
https://pubmed.ncbi.nlm.nih.gov/30628057
https://pubmed.ncbi.nlm.nih.gov/30628057
Autor:
Xiangying Xia, Hongxia Zhu, Yamei Yu, Ningzhi Xu, Xixi Wang, Weiliang Lu, Peng Zhang, Dan Zhang, Hanshuo Yang, Shi Deng, Shufang Liang
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 1, p e0170453 (2017)
PLoS ONE, Vol 12, Iss 1, p e0170453 (2017)
Progesterone receptor membrane component 1 (PGRMC1) is widely observed with an elevated level in multiple human cancers. However, the roles of PGRMC1 in renal cancer are not clear and merit further study. In this report, we made a systematic, integra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b1e30ea2654af65ff23812f8bf3aa0b
https://pubmed.ncbi.nlm.nih.gov/28107520
https://pubmed.ncbi.nlm.nih.gov/28107520
Autor:
Zhizhong Xu, Guobo Shen, Xiangying Xia, Xinyu Zhao, Peng Zhang, Huanhuan Wu, Qingfa Guo, Zhiyong Qian, Yuquan Wei, Shufang Liang, Xu, Zhizhong, Shen, Guobo, Xia, Xiangying, Zhao, Xinyu, Zhang, Peng, Wu, Huanhuan, Guo, Qingfa, Qian, Zhiyong, Wei, Yuquan, Liang, Shufang
Publikováno v:
Journal of Translational Medicine; 2010 Supplement 1, Vol. 9 Issue Suppl 1, p46-55, 10p
Autor:
Guobo Shen, Shufang Liang, Zhizhong Xu, Liangxue Zhou, Shiyin Xiao, Xiangying Xia, Ronghui Li, Ying Liao, Chao You, Yuquan Wei
Publikováno v:
Proteome Science; 2010, Vol. 8, p17-28, 12p
Autor:
Yuquan Wei, Ronghui Li, Shiyin Xiao, Chao You, Guobo Shen, Zhizhong Xu, Liangxue Zhou, Xiangying Xia, Shufang Liang, Ying Liao
Publikováno v:
Proteome Science, Vol 8, Iss 1, p 17 (2010)
Proteome Science
Proteome Science
Background Heat shock proteins (HSPs), including mainly HSP110, HSP90, HSP70, HSP60 and small HSP families, are evolutionary conserved proteins involved in various cellular processes. Abnormal expression of HSPs has been detected in several tumor typ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21454d9cc47d5f4d04e6527db6befe15